Weir MR, et al. - A scrutiny was carried out of the efficacy and safety of patiromer in a prespecified subgroup of patients aged ≥65 years from OPAL-HK. The results unveiled that patiromer reduced serum potassium and recurrent hyperkalemia. It was discovered to be well tolerated in older patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors (RAASi).